Connect with us

Cannabis

Love Hemp Thriving in 2020 Leading the Way for World High Life in the CBD and Hemp Markets

GlobeNewswire

Published

on

NEW YORK, NY, June 29, 2020 (GLOBE NEWSWIRE) — World High Life’s (OTCQB: WRHLF) wholly owned subsidiary, Love Hemp, is embracing the idea, “when life gives you lemons, make lemonade.”  In early 2020, COVID-19 turned into a global pandemic, and in an instant, created a tough environment for both businesses and consumers alike.  Tony Calamita, the CEO of Love Hemp, a London-based CBD company playing a leadership role in the development of the United Kingdom’s (UK) leading range of trusted CBD products, accepted the challenge and has capitalized on these tough times with a dramatic surge in online sales.While the world began to lock down and shelter-in-place, Calamita’s team got creative by dedicating all of Love Hemp’s resources and team to building upon their advanced e-commerce platforms—realizing that the major retail path would be beyond their control during the pandemic.  As a result, consumers began to engage with the company in an unprecedented fashion, and Love Hemp, with its multiple e-commerce platforms, has accelerated its online brand strategy months ahead of planned targets.And Love Hemp’s strategy and execution has worked to perfection.World High Life announced that Love Hemp’s online sales in May 2020 eclipsed online sales figures from January 2020 by an astounding 107%.  These numbers come on the heels of month-over-month growth every single month since January.  The year 2020, while dismal for many businesses across the globe, has been a breakout campaign for Love Hemp—a company that expects the jump in sales during the pandemic to lead to longer-term gains—all while putting World High Life and its efforts to grow an investment portfolio in the legal medicinal cannabis, hemp and CBD industries, on the map as a serious competitor in these industries.Brands, like Love Hemp, that have enjoyed a surge in online sales have most likely also enjoyed a rush of first-time customers giving them a monumental opportunity to differentiate themselves from other brands with what is a captive audience experiencing new innovative products as they’re rolled out among the already-popular choices.Love Hemp already has over 80 products, including oils, sprays, edibles, cosmetics, and vapes, and has around 1,200 retail listings.  Combined, these products have positioned the company as one of the UK’s leading CBD and hemp product suppliers, but the company isn’t stopping there because as Love Hemp’s CEO points out, the company is always expanding its product line to meet the demands of its growing customer base.  “Love Hemp has always been passionate about creating a leading range of trusted CBD products.  Over the past few years, we have seen the demand for CBD products soar in the UK as more and more people become aware of its benefits to well-being.”  Tony Calamita continued, “New product development is at the heart of our business—we were the first functional spring water in Europe to be infused with CBD.  Oils, sprays, vapes, chocolate, jelly domes, and beauty products, including the first CBD-infused face masks and body salves, have all followed.”One such product that illustrates Love Hemp’s desire to meet consumer demand is Love Hemp Immune.  The company successfully pushed this product to market well ahead of schedule to meet the needs of consumers.  It is an innovative product that truly confronts the current times we’re all living in, so Calamita and his team made it a priority to launch it sooner rather than later.  Love Hemp Immune is made with the highest quality ingredients, including a combination of CBD, Vitamin C, Vitamin D, and Bilberry extract.  It contains all of the essential supplements that support a healthy immune system, and the company says it’s available in both a 100 ml atomizer spray, as well as, in capsule form.Calamita said of the early release, “We were due to launch Love Hemp Immune in the Winter of 2020, but we have worked around the clock to get it to consumers sooner—and moved forward the launch by six months—launching it in April 2020 instead.  Boosting our immune systems has rarely felt more urgent than now, and Love Hemp Immune contains the perfect combination of beneficial ingredients that will help boost the body’s natural defenses.”Last month World High Life announced that Love Hemp is achieving its plans of growth and brand expansion with a host of notable highlights, including:The Love Hemp brand (www.love-hemp.com) has secured a number of notable listings with leading retailers, such as Boots to complement its existing listings with Ocado, Holland and Barrett, and Sainsbury’s.According to Alliance Healthcare, the UK’s leading distributor to pharmacies and independent retailers, the Love Hemp brand is now its best-selling CBD brand.The brand is in negotiations with some of the largest retailers in the UK for multiple new product listings.To support the growing demand and sales of its products, Love Hemp’s secondary online retailer, CBDOilsUK (www.cbdoilsuk.com), is expanding its product portfolio with three new brands and a renewed web presence in the near future.LH Botanicals (www.lhbotanicals.com), Love Hemp’s CBD wholesale production business, is adding production capacity and new product lines with the acquisition of new machines.Brightfield Group, the leading consumer insights and market intelligence firm for the CBD and cannabis industries said of weathering the pandemic, “Smaller brands often rely on small or local retailers to distribute the bulk of their products.  In the current environment, mass shuttering of retailers is likely to deal a death blow to many of the smaller brands in the market.  This could actually work in favor of many of the larger brands, who are better positioned to weather the storm and be able to support a robust e-comm strategy.  If they can keep the lights on over the next few months, they may be competing in a much less crowded field once we emerge from the crisis.”Love Hemp, however, is unlike many smaller brands and has proven that it is an exception to the rule as it is not only weathering these tough times but thriving in them.  The company’s success is likely due to the infrastructure it already had in place to prosper in times like these. Love Hemp has its own wholesale production business with LH Botanicals, which is the UK’s biggest seed-to-shelf premium CBD supplier.  It provides a complete range of CBD products for wholesale, bulk, and white label and it works with brands to formulate and develop their own finished products.  Additionally, Love Hemp has its own secondary online retailer, and it has already secured shelf space in pharmacies and with leading retailers, and the company has a team that is constantly thinking outside-the-box to develop new products and negotiate shelf space with some of the UK’s largest retailers.Brightfield Group released new consumer research in mid-March 2020 that indicated, anxiety rated as the highest ailment among CBD users with depression and insomnia following close behind.  But, interestingly, Brightfield Group found that self-care products have become a popular topic on social media.  With much of the world in quarantine or slowly emerging from it right now, Brightfield Group says, “many are turning to self-care indulgences to keep themselves sane and even just pass the time, which is likely to help boost some CBD self-care products during quarantine time.”Love Hemp is in a position to offer products that can help with what is ailing each of these groups.  First, all of the company’s products have certified CBD concentration and are certified to be 100% THC free.  Globally there is growing awareness about the possible health benefits of CBD oil, including for anxiety relief, as an anti-seizure solution, for pain relief, as a neuroprotective, etc., and Love Hemp even offers self-care products.Brightfield Group has estimated significant growth over the next four years in the European market.  The firm’s research expects 400% growth in Europe’s legal cannabis market by the end of 2023, and with Love Hemp situated in the UK and succeeding, it is in an ideal position to capture a large share of that growing European market.  Read about World High Life/Love Hemp’s planned brand expansion in other global CBD markets: https://www.globenewswire.com/news-release/2020/06/15/2048074/0/en/World-High-Life-Subsidiary-Continues-Massive-Sales-Growth-in-the-UK-CBD-Market-with-Eye-to-Future-Brand-Expansion.htmlTo learn more about World High Life visit: https://www.worldhighlife.ukTo learn more about Love Hemp visit: https://love-hemp.comOr to ask questions directly, call their toll-free number in North America: 1 (888) 616-WRHLF (9745)About World High LifeWorld High Life PLC is an investment company with a strategic focus to invest in and/or acquire companies operating in the CBD wellness and medicinal cannabis industry.  The Company’s wholly owned subsidiary, Love Hemp Ltd., is one of the UK’s leading CBD and Hemp product suppliers and has more than 40 product lines, comprising oils, sprays and vapes, and a variety of edible and water-based CBD products.  Love Hemp has established relationships with over 1,200 stores in the UK, including leading brands such as Ocado, Holland & Barrett, and WH Smith.About Stock Market Media GroupStock Market Media Group is a news & media content development IR firm offering a platform for corporate stories to unfold in the media with press releases, research reports, corporate videos, radio-style CEO interviews, and feature news articles.This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets, and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov, where you can also find all of World High Life’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about World High Life are not a recommendation to buy or sell a security.Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company’s profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, two hundred dollars paid for by a third party (three-thousand, six hundred dollars total to date) via bank wire, to produce content related to World High Life.Stock Market Media Group and its management do not own any shares in World High Life and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company’s stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company’s profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.For more information: www.stockmarketmediagroup.com.Contact:Stock Market Media Group info@stockmarketmediagroup.com

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Yield Growth Announces Manufacturing of Plant-Based Deodorant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – July 9, 2020) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that it has completed an initial 5,000 product run of a new deodorant SKU for plant-based brand, Antler.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2020/07/yield-growth-announces-manufacturing-of-plant-based-deodorant.jpg?w=740&ssl=1
Yield Growth Announces Manufacturing of Plant-Based Deodorant

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6377/59426_yield2.jpg

“I am proud of our accomplishments in manufacturing plant-based products,” says Yield Growth Chief Executive Officer Penny White. “The timing is right for a high quality men’s plant-based wellness line, and we are pleased to be able to manufacture the highest quality products for Kingdom Brands.”

Kingdom Brands retained Yield Growth to manufacture the deodorants, which is part of a full plant-based men’s wellness collection under the Antler brand. Yield Growth completed production of Antler Deodorant as a white label for Kingdom Brands this month. This long-lasting, all natural, plant-based, aluminium-free deodorant is especially well suited for sensitive skin, is packaged to comply with U.S. and Canadian retail regulations, and can be sold directly to consumers via e-commerce.

There are no parabens, sulphates or aluminum in the Antler deodorant, which is vegan friendly and gluten free. The ingredients include a mix of hemp seed oil, coconut oil and shea butter base, which are all rich in fatty acid. Also incorporated are vitamins and antioxidants known to keep the skin moisturized and hydrated for a soothing and softer skin texture, mixed with sodium bicarbonate, a natural and safe mineral to neutralize odor causing bacteria.

According to a report by Future Market Insights, the global aluminium-free deodorant market is estimated at around US$1.2 billion in 2019, and is expected to grow at a CAGR of nearly 10% from 2019 to 2029.

About The Yield Growth Corp.

The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) is a phytoceutical and consumer packaged goods company that develops and acquires intellectual property and other assets related to plant-based products and therapeutics, and develops, manufactures, markets, sells and distributes plant-based products that improve lives. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 products that are now for sale through e-commerce or brick and mortar retail stores. It owns the plant-based skin care brand Urban Juve, which is currently launching several hand sanitizer products, and it owns wellness brands Wright & Well and Jack n Jane. Yield Growth owns almost 20% of plant based wellness and clothing brand company Kingdom Brands, which is launching plant based products for men. It has 14 patent applications for its extraction method and product formulations and filed in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. It is developing natural health products, including sunscreen, pain balm, and skin topicals to fight and ward off infectious diseases. Its majority owned subsidiary NeonMind Biosciences Inc. is launching a line of medicinal mushroom products and is developing intellectual property in the emerging area of psychedelic medicine. The Yield Growth management and advisory team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, Skechers and Aritzia.

Investor Relations Contacts:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies do to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59426

Continue Reading

Cannabis

Materia and Pure Ratios to Launch Award-Winning CBD Topicals into the UK Market

Vlad Poptamas

Published

on

 

Materia (“Materia” or the “Company“), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc. (“Pure Ratios”), an award-winning CBD topical manufacturer and subsidiary of 4Front Ventures Corp (CSE: FFNT) (OTCQX: FFNTF), to distribute and market its products across Europe.

“Pure Ratios is an innovator, with a best-in-class transdermal patch, rooted in science and natural medicine. We are excited to be their European partner, with plans to launch in the UK as our first market,” said Deepak Anand, CEO of Materia. “The UK is currently Europe’s largest CBD market and consumers are developing brand preference for products they like and trust. The market research we have conducted, including consumer segmentation and brand mapping, has made clear the calibre of partners required for long-term success. With highly differentiated products, proven quality and an established track record with consumers, Pure Ratios fits this profile perfectly.”

Founded in 2015 and based in San Diego, California, Pure Ratios is known for combining holistic wellness concepts with CBD and other cannabinoids. Its award-winning line of CBD topical patches are sold through a network of over 1000 stores across the United States and through their expanding e-commerce and distribution platforms. Under the terms of the agreement, Materia will conduct sales and marketing for Pure Ratios’ hemp-derived CBD topical salve, topical roll-on, lip balm and 96-hour transdermal reservoir patch products. Materia will work directly with wholesalers, retailers, and direct to consumers channels in the UK.

“Our approach of combining modern cannabis science with natural holistic medicine is both unique and effective and that has helped establish Pure Ratios as one of the most reputable CBD brands in the US,” said Chad Conner, Co-Founder of Pure Ratios. “We selected Materia as our partner because they have the commercial acumen and regulatory expertise to help navigate the burgeoning European market opportunity for us to propel Pure Ratios into a leading global wellness brand.”

According to the Centre for Medical Cannabis, UK consumers are spending over £300 million a year on CBD products and the market is forecasted to grow to almost £1 billion by 20251.  Demand for topicals is expected to exceed overall growth in the CBD market with a CAGR greater than 20%1. Key topical formats are balms and gels that are being used for muscle and joint relief, as well as skincare creams. The global CBD skincare market alone is expected to expand at a CAGR of 32.9% from 2019 to 2025, thereby reaching a value of approximately £1.4 billion (USD $1.7 billion) by 20252.

Continue Reading

Cannabis

InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments

Newsfile

Published

on

Herzeliya, Israel and Calgary, Alberta–(Newsfile Corp. – July 9, 2020) – InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.

Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from Recipharm development facilities and provide commercial supply of a wide range of formulations. Recipharm has over 25 years of experience innovating and developing new technologies and processes for clinical applications. Recipharm’s facility in Israel, offers development services to a wide variety of clients from start-ups to large established companies. Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

Iris Bincovich, InnoCan’s CEO stated: “Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm.”

Dr. Sylvia Kachalsky, site manager in Israel stated: “We are very exiting to work with InnoCan Pharma on this unique project who has a potential to be applied on large spectrum of different indications. The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a “targeted missile” leading the chosen Cannabinoid to its target.”

Prof. Dani Offen stated: “The development of the CLX- CBD loaded Exosome is very challenging but holding huge potential. Working with Recipharm will allow me and my team to be concentrating and putting all efforts at the Exosome production/characterization/loading side of the development process while knowing the analysis work is been done in one of the best labs we could chose. We are working with Recipharm in close collaboration on the development of this exiting technology and looking forward to achieve the milestones as we planned.”

About Innocan Pharma

The Company, through its wholly-owned subsidiary, Innocan Pharma Ltd. (“Innocan Pharma Israel“), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“) with other pharmaceutical ingredients. Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the COVID-19 coronavirus. CBD-loaded exosomes may hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Pharma Israel has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, plans to test the liposome platform on several potential indications. The Company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately Euro 1.1 Billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59362

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania